Bibliography
- BRODIE A, NJAR VCO: Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications. I Steroid Biochem. Malec. Biol. (1998) 66:1–10.
- BRODIE A, NJAR VCO: Comprehensive pharmacology and clinical efficacy of aromatase inhibitors. Drugs (1999) 58:233–255.
- •Comprehensive review on clinically used aromatase inhibitors.
- RECANATINI M, CAVALLI A, VALENTI P: Nonsteroidal aromatase inhibitors: recent advances. Med. Res. Rev (2002) 22:282–304.
- ••An excellent review on non-steroidalaromatase inhibitors, emphasising new compounds and their activity.
- LEPHART ED: A review of brain aromatase cytochrome P450. Thant Res. Rev (1996) 22:1–26.
- BRODIE A, LONG B: Aromatase inhibitionand inactivation. Gin. Cancer Res. (2001) 7:S4343–S4349.
- BRODIE A, LONG B, LU Q: Aromatase expression in the human breast. Breast Cancer Res. B. (1998) 53:S85–S91.
- SANTEN RJ, MARTEL J, HOAGLAND M et al.: Demonstration of aromatase activity and its regulation in breast tumor and benign breast fibroblast. Breast Cancer Res. Tr. (1998) 53:S93–S99.
- BRODIE AMH, LU Q, LONG B: Aromatase and cox-2 expression in human breast cancer. J. Steroid Biochem. (2001) 607:1–7.
- BANTING L, NICHOLLS PJ, SHAW MA, SMITHRecent developments inaromatase inhibition as a potential treatment for oestrogen-dependent breast cancer. Progr. Med. Chem. (1989) 26:253–298.
- BANTING L: Inhibition of aromatase. Progr. Med. Chem. (1996) 33:147–184.
- •Two manuscripts on compounds developed as aromatase inhibitors up to 1996.
- SERALINI G, MOSLEMI S: Aromatase inhibitors: past, present and future. Ma Cell. Endocrinol (2001) 178:117–131.
- NUMAZAWA M, OSHIBE M, YAMAGUCHI S, TACHIBANA M: Time-dependent inactivation of aromatase by 6-alkylandrosta-1,4-diene-3,17-dione. Effects of length and configuration of the 6-alkyl group. j Med. Chem. (1996) 39:1033–1038.
- NUMAZAWA M, OSHIBE M, YAMAGUCHI S, TACHIBANA M: Enzymic aromatization of 6-alkyl-substitute androgens, potent competitive and mechanism-based inhibitors of aromatase. Bioch. J. (1998) 329:151–156.
- AKKANI A, PATERLINI G, GLEASON WB et al.: 613-propynyl-substituted steroids: mechanism-based enzyme-activated irreversible inhibitors of aromatase. J. Med. Chem. (1997) 40:3263–3270.
- KITZ R, WILSON IB: Esters of methansulfonic acid as irreversible inhibitors of acetylcholinesterase. J. Biol. Chem. (1962) 237:3425–3249.
- HARTMANN RW, FROTSCHER M, LEDERGERBER D et al.: Synthesis and evaluation of azole-substituted tetrahydronaphtalenes as inhibitors of P450 arom, P450 17, and P450 TxA2. Arch. Pharm. Med. Chem. (1996) 329:251–256.
- WACHTER GA, HARTMANN RW, SERGEJEW TF et al.: Tetrahydronaphtalenes: influence of heterocyclic substituents on inhibition of steroidogenic enzymes P450 arom and P450 17. J. Med. Chem. (1996) 39:834–841.
- NJAR VC, BRODIE AM: Inhibitors of 17a-hydroxylase/17, 20-lyase (CYP 17) : potential agents for the treatment of prostate cancer. Carr. Pharm. Des. (1999) 5:163–180.
- HARTMANN RW, EHMER PB, HAIDAR S et al.: Inhibition of CYP17, a new strategy for the treatment of prostate cancer. Arch. Pharm. (2002) 335:119–128.
- BRUEGGEMEIER RW: Aromatase, aromatase inhibitors, and breast cancer. Am. Ther. (2001) 8:333–344.
- RAMAN JD, SCHLEGEL PN: Aromatase inhibitors for male infertility. j. Um]. (2002) 167:624–629.
- SANTEN RJ, PETRONI GR, FISCH MJ et al.: Use of aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma. Cancer (2001) 92:2095–2101.
- BULUN SE, NOBLE SL, TAKAYAMA K et al.: Endocrine disorders associated with inappropriately high aromatase expression. Steroid Biochem. Molec. Bin] (1997) 61:133–139.
- TURNER KJ, MORLEY M, ATANASSOVA N, SWANSTON ID, SHARPE RM: Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. I Endocrinol (2000) 164:225–238.
- BRAUNSTEIN GD: Aromatase and gynecomastia. Endocr. Relat. Cancer (1999) 6:315–324.
- MURRAY R: Role of anti-aromatase agentsin postmenopausal advanced breast cancer. Cancer Chemother. Pharmacol (2001) 48:259–265.
- KELLOFF GJ, SIGMAN CC, GREENWALD P: Cancer chemoprevention: progress and promise. Ear: j Cancer(1999) 35:1755–1762.
- LUBET RA, STEELE VE, CASEBOLT TL, ETO I, KELLOFF GJ, GRUBBS CJ: Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosurea (MNU)-induced mammary tumor model in Sprague-Dawley rats. Carcinogenesis (1994) 15:2775–2780.
- GUNSON DE, STEELE RE, CHAU RY: Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor. Br. J. Cancer (1995) 72:72–75.
- KELLOFF GJ, LUBET RA, LIEBERMAN R et al.: Aromatase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomark. Prey (1998) 7:65–78.
- ••Review on aromatase inhibitors and theirpotential use in cancer chemoprevention.
- VAN LANDEGHEM AAJ, POORTMAN J, NABUURS M et al.: Endogenous concentration and subcellular distribution of estrogen in normal and malignant human breast tissue. Cancer Res. (1985) 45:2900–2906.
- VERMEULEN A, DESLYPERE JP, PARIDAENS R et al: Aromatase, 1713 hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal breast tissue in post-menopausal women. Ear: JCancer Oncol (1986) 22:515–525.
- YUE W, WANG J, HAMILTON CJ et al.: In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res. (1998) 58: 927–932.
- GRADISHAR WJ, JORDAN VC: Clinical potential of new antiestrogens.Oncol(1997) 15:840–852.
- WALKER RA, DEARING SJ: Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res. B. (1999) 53:167–176.
- RICHARDS JA, PETREL TA, BRUEGGEMEIER RW: Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells. Steroid Biochem. Molec. Biol. (2002) 80:203–212.
- SLAMON DJ, GODOLPHIN W, JONES LA: Studies of the HER-21 neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244:707–712.
- BRUEGGEMEIER RW: Aromatase inhibitors in breast cancer therapy. Expert Rev Anticancer The]: (2002) 2:181–191.
- ••An excellent review on aromatase inhibitorsused in breast cancer treatment.
- SHARPE RIVI: The roles of oestrogen in themale. Trends Endocrin. Met. (1998) 9:371–377.
- MAHLER C, VERHELST J, DENIS L: Clinical pharmacocinetics of the antiandrogens and their efficacy in prostate cancer. Gin. Pharmacokinet. (1998) 34:405–417.
- COMHAIRE FH, ROMBAUTS L, VEREECKEN A et al: Inhibin and steroid responses to testicular stimulation in normal men. Human Rep. (1995) 10:1740–1744.
- AHOKOSKI O, IRJALA K, HUHTALA S et al.: A double-blind study of MPV-2213ad, a novel aromatase inhibitor, in healthy male subjects. Eur. Clin. Pharmacol (1999) 55:27–34.
- AHOKOSKI O, IRJALA K, TAALIKKA M et al: Pharmacokinetics of finrozole (MPV-2213ad), a novel selective aromatase inhibitor, in healthy man. Br. j Clin. Pharmacol (2001) 52:702–704.
- KARJALAINEN A, KALAPUDAS A, SODERVALL M et al.: Synthesis of new potent and selective aromatase inhibitors based on long-chained diarylalkylimidazole and diarylalkyltriazole molecule skeletons. Eur. Pharm. Sci. (2000) 11:109–131.
- BUZDAR A: A summary of second-line randomized studies of aromatase inhibitors. Steroid Biochem. Molec. Biol. (2001) 79:109–114.
- MOURIDSEN H, GERSHANOVICH M, SUN Y et al.: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast cancer Group. J. Clin. Oncol (2001) 19:2596–606.
- RAGAZ J: Adjuvant trials of aromatase inhibitors: determining the future landscape of adjuvant endocrine therapy. j Steroid Biochern. Molec. Biol. (2001) 79:133–141.
- GOSS PE: Preliminary data from ongoing adjuvant aromatase inhibitor trials. Clin. Cancer Res. (2001) 7:S4397–S4401.
- •Manuscript provides preliminary results from clinical trials on aromatase inhibitors in adjuvant breast cancer therapy.
- GOSS PE, STRASSER K: Tamoxifen resistant and refractory breast cancer. Drugs (2002) 62:957–966.
- ELLIS MJ, COOP A, SINGH B et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen-receptor positive primary breast cancer: evidence from a phase III randomized trial.," Clin. Oncol. (2001) 19:3808–3816.
- EIERMAN W, PAEPKE S, APPFELSTAEDT J et al.: Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized multicenter study. Ann. Oncol. (2001) 12:1527–32.
- •Two manuscripts describe the results from clinical trials on letrozole in neoadjuvant breast cancer treatment.
- LONNING PE, KRAGH LE, ERIKSTEIN B et al.: The potential for aromatase inhibition in breast cancer prevention. Clin. Cancer Res. (2001) 7:S4423–S4428.
- GOSS PE, STRASSER K: Chemoprevention with aromatase inhibitors-trial strategies. I Steroid Biochern. Molec. Biol. (2001) 79:143–149.
- FABIAN CJ, KIMLER BF: Beyond tamoxifen: new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention. Ann. NY Acad. Sci. (2001) 952:44–59.
- FOWLER KA, GILL K, KIRMA K et al: Overexpression of aromatase leads to development of testicular Leydig cell tumors. Am. J. Patna (2000) 156:347–355.
- FEUILLAN P, MERKE D, LESCHEK EW et al.: Use of aromatase inhibitors in precocious puberty. Erma: Relat. Cancer (1999) 6:315–324.
- BULUN SE, NOBLE SL, TAKAYAMA K et al.: Endocrine disorders associated with inappropriately high aromatase expression. J. Steroid Biochein. Molec. Biol. (1997) 61:133–139.
- BULUN SE, YANG S, FANG Z et al: Estrogen production and metabolism in endometriosis. Ann. NY Acad. Sci. (2002) 955:75–85.
- FIORELI G, PISCARIELLO L, MARTINETI Vet al: Estrogen synthesis in human colon cancer epithelial cells. Steroid. Biochern. Molec. Biol. (1999) 71:223–230.
Websites
- http://www.cancer.org/downloads/STT/ CancerFacts&Figures 192002TM.pdf American Cancer Society facts and figures.